The col­lapse of SKY­SCRAPER-01 is cast­ing a pall over all the TIG­ITs. Are we in for an­oth­er I/O fi­as­co?

The first time Roche re­port­ed a fail­ure for its sweep­ing Phase III pro­gram for the TIG­IT con­tender tiragolum­ab a cou­ple of months ago, quite a few an­a­lysts were will­ing to give the drug — and the class — a pass.

But when the Swiss gi­ant flagged the col­lapse of the PFS end­point in SKY­SCRAPER-01 in the wee hours of the Amer­i­can mar­ket to­day, there was no mis­tak­ing the dark cloud that took shape over the field as the an­a­lyst crew shook their heads over the prospects for what had been the lat­est, great­est hope for im­muno-on­col­o­gy 2.0.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE